Eli Lilly and Company· @EliLillyandCo · X·· 16 小时前精选AI 评分47
AI 导读
礼来在EASD2026公布其一款在研疗法的新研究数据，最高剂量下超过一半受试者不再患肥胖症，近40%受试者A1C达到正常水平。该疗法针对肥胖与2型糖尿病同时治疗这一难点，目前仍处于在研阶段。
推荐理由
礼来在EASD2026公布的在研疗法最高剂量数据，给出了减重与降糖两项终点的人群比例。
正文
Treating obesity & type 2 diabetes together can be challenging, but new research presented at #EASD2026 showed our investigational treatment, when taken at the highest dose, helped more than half of participants no longer have obesity, and nearly 40% reach a normal A1C. https://go.lilly.com/fiqcmh
来源：Eli Lilly and Company · x.com